Overview

Effects of cKit Inhibition by Imatinib in Patients With Severe Refractory Asthma (KIA)

Status:
Completed
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see whether a new investigational drug (Imatinib) may help improve asthma in people whose symptoms are not well controlled with high dose inhaled corticosteroid treatment.
Phase:
Phase 2
Details
Lead Sponsor:
Brigham and Women's Hospital
Collaborators:
Baim Institute for Clinical Research
Harvard Clinical Research Institute
National Heart, Lung, and Blood Institute (NHLBI)
Treatments:
Imatinib Mesylate